LLY

877.97

+0.77%↑

UNH

526.48

-0.54%↓

JNJ

153.08

-0.26%↓

ABBV

190.7

-1.19%↓

MRK

87.25

-0.84%↓

LLY

877.97

+0.77%↑

UNH

526.48

-0.54%↓

JNJ

153.08

-0.26%↓

ABBV

190.7

-1.19%↓

MRK

87.25

-0.84%↓

LLY

877.97

+0.77%↑

UNH

526.48

-0.54%↓

JNJ

153.08

-0.26%↓

ABBV

190.7

-1.19%↓

MRK

87.25

-0.84%↓

LLY

877.97

+0.77%↑

UNH

526.48

-0.54%↓

JNJ

153.08

-0.26%↓

ABBV

190.7

-1.19%↓

MRK

87.25

-0.84%↓

LLY

877.97

+0.77%↑

UNH

526.48

-0.54%↓

JNJ

153.08

-0.26%↓

ABBV

190.7

-1.19%↓

MRK

87.25

-0.84%↓

Search

Novo Nordisk A-S

Cerrado

Sector Salud

86.38 -0.88

Resumen

Variación precio

24h

Actual

Mínimo

86.08

Máximo

88.59

Métricas clave

By Trading Economics

Ingresos

7.3B

27B

Ventas

3.3B

71B

P/B

Media del Sector

39.59

59.362

BPA

6.12

Rentabilidad por dividendo

1.258

Margen de beneficio

38.285

EBITDA

233M

36B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+14.83 upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

1.26%

2.35%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-2.3B

285B

Apertura anterior

87.26

Cierre anterior

86.38

Noticias sobre sentimiento de mercado

By Acuity

66%

34%

341 / 393 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Novo Nordisk A-S Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

5 feb 2025, 11:53 UTC

Ganancias

Novo Nordisk Outlook Provides Some Welcome Relief -- 2nd Update

5 feb 2025, 08:19 UTC

Ganancias

Novo Nordisk Expects Slowing Sales Growth This Year -- Update

7 feb 2025, 10:30 UTC

Principales Noticias

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 feb 2025, 16:16 UTC

Principales Noticias
Ganancias

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6 feb 2025, 14:56 UTC

Ganancias

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

5 feb 2025, 13:59 UTC

Ganancias

Novo Nordisk Outlook Provides Some Welcome Relief -- WSJ

5 feb 2025, 12:02 UTC

Ganancias

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns. -- Barrons.com

5 feb 2025, 11:35 UTC

Charlas de Mercado
Ganancias

Novo Nordisk's Earnings Report Should Get It Back On Track -- Market Talk

5 feb 2025, 10:10 UTC

Acciones populares

Stocks to Watch Wednesday: AMD, Alphabet, Novo Nordisk -- WSJ

5 feb 2025, 09:43 UTC

Ganancias

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5 feb 2025, 08:47 UTC

Charlas de Mercado
Ganancias

Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk

5 feb 2025, 08:38 UTC

Charlas de Mercado
Ganancias

Novo Nordisk Earnings, Guidance Imply Consensus Upgrades -- Market Talk

5 feb 2025, 08:32 UTC

Ganancias

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5 feb 2025, 08:30 UTC

Charlas de Mercado
Ganancias

Novo Nordisk Sales Guidance Materially Ahead of Expectations -- Market Talk

5 feb 2025, 06:46 UTC

Ganancias

Novo Nordisk Expects to File For First Regulatory Approval of CagriSema During 1Q26

5 feb 2025, 06:45 UTC

Ganancias

Novo Nordisk Plans to Initiate New CagriSema Phase 3 Trial in 2025 to Further Explore Weight Loss Potential

5 feb 2025, 06:43 UTC

Ganancias

Novo Nordisk: 2025 Free Cash Flow Expected to be DKK75B-DKK85B

5 feb 2025, 06:42 UTC

Ganancias

Novo Nordisk: 2025 Capex Expected to be Around DKK65B, Reflecting Expansion of Global Supply Chain

5 feb 2025, 06:39 UTC

Ganancias

Novo Nordisk: Sales Growth Has Resulted in Periodic Supply Constraints and Related Drug Shortage Notifications

5 feb 2025, 06:39 UTC

Ganancias

Novo Nordisk: Sales Growth Positively Impacted by Gross-to-Net Adjustments in U.S.

5 feb 2025, 06:35 UTC

Ganancias

Novo Nordisk 4Q Wegovy Sales DKK19.87B, Analysts Saw DKK20.04B

5 feb 2025, 06:35 UTC

Ganancias

Novo Nordisk 4Q Ozempic Sales DKK33.85, Analysts Saw DKK33.34B

5 feb 2025, 06:34 UTC

Ganancias

Novo Nordisk: 4Q Gross Margin 84.8% Vs 84.8%, EBIT Margin 42.9% Vs 40.6%

5 feb 2025, 06:33 UTC

Ganancias

Novo Nordisk: Analysts Saw 4Q Net Profit At DKK26.06B

5 feb 2025, 06:33 UTC

Ganancias

Novo Nordisk 4Q Net Pft DKK28.23B

5 feb 2025, 06:33 UTC

Ganancias

Novo Nordisk: Analysts Saw 4Q Op Pft At DKK33.31B

5 feb 2025, 06:33 UTC

Ganancias

Novo Nordisk 4Q Oper Pft DKK36.74B

5 feb 2025, 06:33 UTC

Ganancias

Novo Nordisk: Analysts Saw 4Q Sales At DKK80.14B

5 feb 2025, 06:33 UTC

Ganancias

Novo Nordisk 4Q Sales DKK85.68B

5 feb 2025, 06:32 UTC

Ganancias

Novo Nordisk Declares Final Dividend of DKK7.90

Comparación entre iguales

Cambio de precio

Novo Nordisk A-S Esperado

Precio Objetivo

By TipRanks

14.83% repunte

Estimación a 12 meses

Media 100.1 USD  14.83%

Máximo 124 USD

Mínimo 81.5 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novo Nordisk A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

8 ratings

5

Comprar

2

Mantener

1

Vender

Puntuación técnica

By Trading Central

85.19 / 87.51Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

341 / 393 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Novo Nordisk A-S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.